Skip to content
Menu

Baird Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $875

Benzinga Newsdesk 2 weeks ago

Analyst RatingsNewsPrice TargetHot

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Baird analyst Brian Skorney maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and raises the price target from $761 to $875.

Baird analyst Brian Skorney maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and raises the price target from $761 to $875.

Read at benzinga.com

← All stock news